India, Aug. 30 -- Tenax Therapeutics Inc. (TENX), a development-stage pharmaceutical company, on Friday announced clinical results from the Phase 3 LEVEL trial for TNX-103 in patients with pulmonary hypertension associated with heart failure preserved ejection fraction. The data was presented at a Late-Breaking Clinical Science session at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany.
Pulmonary Hypertension associated with Heart Failure preserved Ejection Fraction (PH-HFpEF) is the Group 2 subtype of pulmonary hypertension that develops due to left-sided heart disease. In patients with PH-HFpEF, chronic heart failure leads to increased blood pressure in the pulmonary arteries, exerting severe strain on the right...